Growth Metrics

Pfizer (PFE) Capital Expenditures (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 -48.40%
Dec 31, 2025 40.37%
Sep 28, 2025 -2.59%
Jun 29, 2025 9.57%
Sep 29, 2024 212.72%
Jun 30, 2024 -9.52%
Mar 31, 2024 -32.57%
Dec 31, 2023 28.89%
Oct 1, 2023 -11.38%
Jul 2, 2023 -19.75%
Oct 2, 2022 197.60%
Jul 3, 2022 16.80%
Oct 3, 2021 218.25%
Jul 4, 2021 -3.07%
Sep 27, 2020 209.19%
Jun 28, 2020 1.78%
Mar 29, 2020 -17.16%
Dec 31, 2019 -4.07%
Sep 29, 2019 17.95%
Jun 30, 2019 4.13%
Mar 31, 2019 -26.63%
Dec 31, 2018 14.63%
Sep 30, 2018 29.01%
Jul 1, 2018 9.84%
Apr 1, 2018 -44.86%
Dec 31, 2017 55.56%
Oct 1, 2017 0.45%
Jul 2, 2017 25.14%
Apr 2, 2017 -48.04%
Dec 31, 2016 59.49%
Oct 2, 2016 7.73%
Jul 3, 2016 33.22%
Apr 3, 2016 -50.74%
Dec 31, 2015 111.42%
Sep 27, 2015 12.02%
Jun 28, 2015 7.95%
Mar 29, 2015 -32.49%
Dec 31, 2014 28.73%
Sep 28, 2014 -1.08%
Jun 29, 2014 -4.79%
Mar 30, 2014 -29.98%
Dec 31, 2013 50.00%
Sep 29, 2013 -10.03%
Jun 30, 2013 52.97%
Mar 31, 2013 -59.11%
Dec 31, 2012 73.33%
Sep 30, 2012 -3.06%
Jul 1, 2012 15.75%
Apr 1, 2012 -57.53%
Dec 31, 2011 31.72%
Oct 2, 2011 26.82%
Jul 3, 2011 43.20%
Apr 3, 2011 -54.30%
Dec 31, 2010 89.93%
Oct 3, 2010 -22.79%
Jul 4, 2010 22.30%
Apr 4, 2010 -27.73%
Dec 31, 2009 61.69%
Sep 27, 2009 -2.97%
Jun 28, 2009 6.32%